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Abstract: Purpose: To test the hypothesis that upregulated expression of the proinflammatory cytokine high-mobility 
group box-1 (HMGB1) in the eyes from patients with proliferative diabetic retinopathy (PDR) regulates the expression 
of matrix metalloproteinase-9 (MMP-9) in diabetic retina. Methods: Vitreous samples from 25 PDR and 17 nondia-
betic patients, retinas from 1-month diabetic rats and normal rats intravitreally injected with HMGB1 and human 
retinal microvascular endothelial cells (HRMEC) were studied with the use of enzyme-linked immunosorbent assay, 
Western blot analysis and RT-PCR. We also studied the effects of HMGB1 inhibitor glycyrrhizin and targeted deletion 
of the MMP-9 gene on diabetes-induced biochemical changes in the retina. An assay for in vitro cell migration was 
performed on human retinal microvascular endothelial cells (HRMEC). Results: Levels of HMGB1 and MMP-9 were 
significantly higher in the vitreous fluid from PDR patients compared with nondiabetic patients (P < 0.001 for both 
comparisons) and these were significantly correlated (r = 0.5, P = 0.003). Diabetes induction and intravitreal injec-
tion of HMGB1 in normal rats induced significant upregulation of MMP-9 and downregulation of tissue inhibitor of 
metalloproteinase-1 (TIMP-1) mRNA levels. Constant glycyrrhizin intake from onset of diabetes attenuated diabetes-
induced upregulation of MMP-9, but did not affect TIMP-1 expression in the retina. Deletion of the MMP-9 gene in 
mice did not inhibit diabetes-induced upregulation of HMGB1 in the retina. However, the MMP-9 inhibitor inhibited 
HMGB1-induced MMP-9 upregulation and migration in HRMEC. Conclusions: Our findings suggest that MMP-9 acts 
downstream of HMGB1 and mediates the effect of HMGB1 in diabetic retinopathy.
Keywords: Proliferative diabetic retinopathy, high-mobility group box-1, matrix metalloproteinase-9, angiogenesis, 
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Introduction
Ischemia-induced angiogenesis is a hallmark 
feature of proliferative diabetic retinopathy 
(PDR) and is a critical step in the progression of 
the disease. Angiogenesis, the sprouting of 
new blood vessels from preexisting blood ves-
sels, is a multistep process requiring the degra-
dation of the basement membranes and extra-
cellular matrix (ECM), endothelial cell migration, 
endothelial cell proliferation, and capillary tube 
formation [1]. Vascular endothelial growth fac-
tor (VEGF) is an important angiogenic factor in 
PDR that promotes neovascularization and vas-
cular leakage [2]. The angiogenic switch 
involves in part the proteolytic degradation of 
basement membranes and ECM components 
by matrix metalloproteinases (MMPs) [1]. Se- 
veral studies reported elevated levels of MMPs, 
in particular MMP-9, in the vitreous fluid from 
patients with PDR [3, 4]. This upregulation of 
MMP-9 is linked to angiogenesis and progres-
sion of PDR. MMP-9 expression is low or absent 
in most normal tissues, and is markedly elevat-
ed during inflammatory, autoimmune, degener-
ative and neoplastic diseases and in angiogenic 
lesions [5]. In addition to removing the physical 
barriers against new vessel growth, MMP-9 
releases biologically active VEGF from ECM and 
increases its bioavailability resulting in VEGF-
driven angiogenic switch [6-8]. MMP-9 may 
facilitate pathologic neovascularization through 
stimulation of the production of VEGF [9]. 
MMP-9 has also been shown to be important in 
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mobilizing endothelial and other progenitor 
cells from the bone marrow niche by releasing 
soluble kit-ligand [10]. Most of the MMPs are 
inhibited by specific endogenous tissue inhibi-
tors which are known as tissue inhibitors of 
matrix metalloproteinases (TIMPs) [11].
Chronic, low-grade subclinical inflammation is 
responsible for many of the vascular lesions in 
diabetic retinopathy [12]. The causal relation-
ship between inflammation and angiogenesis 
is now widely accepted [13]. Sustained proin-
flammatory responses are associated with 
increased angiogenesis that contributes to tis-
sue disruption and disease progression [13]. 
An emerging issue in diabetic retinopathy 
research is the focus on the mechanistic link 
between chronic low-grade inflammation and 
angiogenesis. Recently, it was demonstrated 
that the pro-inflammatory cytokine high-mobili-
ty group box-1 protein (HMGB1) seems to be 
involved in a positive feedback mechanism that 
may help to sustain inflammation and angio-
genesis in several pathological conditions, 
thereby contributing to disease progression 
[13, 14]. These findings suggest that HMGB1 
might provide a mechanistic link between 
chronic low-grade inflammation and angio- 
genesis.
HMGB1 was originally identified as a nonhis-
tone DNA binding nuclear protein produced by 
nearly all cell types. It plays an important role in 
chromatin organization and transcriptional reg-
ulation. HMGB1 is released passively from 
necrotic cells, and is actively secreted by differ-
ent cell types, including activated immune 
effector cells and endothelial cells. Extracellular 
HMGB1 functions as a proinflammatory cyto-
kine that triggers inflammation and recruits leu-
kocytes to sites of tissue damage [13, 15-19] 
and exhibits angiogenic effects [19-23]. 
Treatment of endothelial cells with HMGB1 
induced a proangiogenic gene expression pro-
gram evidenced by the induction of VEGF and 
its receptors, platelet-derived growth factor 
receptors, integrins and MMPs. In addition, 
HMGB1 induced endothelial cell migration and 
sprouting. HMGB1 was also identified as a spe-
cific marker of tumor endothelium and as a 
tumor angiogenesis marker. Moreover, anti-
HMGB1 antibodies inhibited tumor angiogene-
sis [19]. Another interesting role of HMGB1 in 
neovascularization is its ability to attract endo-
thelial progenitor cells to sites of tissue injury 
and tumors to improve neovascularization in a 
RAGE-dependent manner [22]. Several recep-
tors have been implicated in HMGB1-mediated 
functions, including receptor for advanced gly-
cation end products (RAGE) and toll-like recep-
tors TLR2, TLR4 and TLR9. Signaling through 
these receptors leads to activation of the extra-
cellular signal-regulated kinase 1 and 2 
(ERK1/2) signaling pathway and the transcrip-
tion factor nuclear factor-kappa B (NF-kB) 
which may alter gene transcription and lead to 
the upregulation of proinflammatory cytokines, 
angiogenic factors, chemokines and adhesion 
molecules and intensify cellular oxidative 
stress [13, 15-18, 24], processes that play a 
role in the pathogenesis of diabetic retinopathy 
development and progression [12, 25-28]. In 
previous studies, we demonstrated increased 
levels of HMGB1 in the vitreous samples from 
patients with PDR [30, 31] and the in situ local-
ization of the expression of HMGB1 and RAGE 
in vascular endothelial cells and stromal cells 
in fibrovascular epiretinal membranes from 
patients with PDR [31]. In addition, we demon-
strated significant correlations between the vit-
reous levels of HMGB1 and the levels of the 
inflammatory biomarkers monocyte chemoat-
tractant protein-1 (MCP-1) and soluble intercel-
lular adhesion molecule-1 (sICAM-1) [29] and 
between the level of vascularization in PDR 
epiretinal membranes and the expression of 
HMGB1 and RAGE [31]. Moreover, we demon-
strated that diabetes and intravitreal injection 
of HMGB1 in normal rats induced significant 
upregulation of the expression of HMGB1, 
RAGE, activated ERK1/2 and activated NF-kB 
in the retinas of rats and mice [29, 32-34]. 
Recently, a great deal of evidence has indicat-
ed the critical importance of HMGB1 in mediat-
ing inflammation, breakdown of the blood-reti-
nal barrier, oxidative stress and neuropathy in 
the diabetic retina [32-35].
Several studies demonstrated that increased 
HMGB1 expression is linked to increased 
MMP-9 expression and activation [36-39]. In 
previous studies we showed HMGB1 (31) and 
MMP-9 [4] localization in vascular endothelial 
cells in PDR fibrovascular epiretinal mem-
branes suggesting a cross-talk between 
HMGB1 and MMP-9 in the pathogenesis of PDR 
angiogenesis and progression. These findings 
suggest that HMGB1-induced angiogenesis in 
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PDR is, at least in part, through upregulation of 
MMP-9. To test this hypothesis, we measured 
and correlated the levels of HMGB1 and MMP-9 
in the vitreous fluid from patients with PDR and 
investigated the expression of MMP-9 and 
TIMP-1 in the retinas of diabetic rats and in the 
retinas of normal rats after intravitreal adminis-
tration of HMGB1. We also examined the effect 
of constant glycyrrhizin intake, a potent HMGB1 
inhibitor [40], on diabetes-induced changes in 
the expression of MMP-9 and TIMP-1 in the reti-
nas of rats. In addition, we examined the effect 
of targeted deletion of the MMP-9 gene in mice 
on diabetes-induced changes in the expression 
of HMGB1 in the retinas. Moreover, we investi-
gated the expression of MMP-9 in human reti-
nal microvascular endothelial cells (HRMEC) 
following exposure to HMGB1, and whether an 
MMP-9 inhibitor blocked HMGB1-induced 




Undiluted vitreous fluid samples (0.3-0.6 ml) 
were obtained from 25 patients with PDR dur-
ing pars plana vitrectomy. The indications for 
vitrectomy were traction retinal detachment, 
and/or nonclearing vitreous hemorrhage. The 
control group consisted of 17 patients who had 
undergone vitrectomy for the treatment of rheg-
matogenous retinal detachment (RD) with no 
proliferative vitreoretinopathy. Controls were 
free from systemic disease. Vitreous samples 
were collected undiluted by manual suction 
into a syringe through the aspiration line of vit-
rectomy, before opening the infusion line. The 
samples were centrifuged (5000 rpm for 10 
min, 4°C) and the supernatants were aliquoted 
and frozen at -80°C until assay. The study was 
conducted according to the tenets of the decla-
ration of Helsinki, and informed consent was 
obtained from all patients. The study was 
approved by the Research Centre, College of 
Medicine, King Saud University.
Enzyme-linked immunosorbent assay kits
Enzyme-linked immunosorbent assay (ELISA) 
kit for Human MMP-9 (Cat No: ab100610) was 
purchased from Abcam, UK. ELISA kit for 
human HMGB1 (Cat No: ST51011), was pur-
chased from IBL international, GMBH, Hamburg, 
Germany. 
The minimum detection limits for MMP-9 and 
HMGB1 ELISA kit were 10 pg/mL, and 200 pg/
mL respectively. The ELISA plate readings were 
done using a Stat Fax-4200, Awareness 
Technology, Inc., Palm City, FL. 
Measurement of MMP-9 and HMGB1 
The quantification of human MMP-9 and 
HMGB1 in the vitreous fluid was determined 
using ELISA kits according to the manufactur-
er’s instruction. For each ELISA, the undiluted 
standard served as the highest standard and 
calibrator diluents served as the zero standard. 
Depending upon the detection range for each 
ELISA the supernatant vitreous obtained were 
used either directly or diluted with calibrator 
diluents supplied with ELISA. 
For the measurement of MMP-9, 100 µL of 
undiluted vitreous were used and added to the 
respective well of ELISA plate. As instructed in 
the kit manual, samples were incubated into 
the each well of ELISA plates. After incubation 
with biotinylated MMP-9 detection antibody, 
horseradish peroxidase (HRP)-Streptavidin 
solution was added to each well of the ELISA 
plate. After incubation and washing, TMB (tetra-
methylbenzidine) substrate solution was added 
for colour development. The reaction was 
stopped by the adding stop solution and OD 
(optical density) was read at 450 nm in a micro-
plate reader. Each assay was performed in 
duplicate.
For the measurement of HMGB1, 50 µL of 2 
fold diluted vitreous samples (sample diluents, 
supplied with the kit) were used in the ELISA 
assay for their analysis. As instructed in the kit 
manual, samples were incubated into the each 
well of ELISA plates. Antibody against HMGB1 
conjugated to HRP was added to each well of 
the ELISA plate. After incubation and washing, 
substrate mix solution (1:1, hydrogen peroxide: 
tetramethylbenzidine) was added for colour 
development. The reaction was stopped by the 
addition of 2N sulfuric acid and the optical 
density (OD) was read at 450 nm in the micro-
plate reader. Each assay was performed in 
duplicate. 
Using the 4-parameter fit logistic (4-PL) curve 
equation, the actual concentration for each 
sample was calculated. For the vitreous fluids, 
that were diluted, the correction read from the 
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standard curve obtained using 4-PL were multi-
plied by the dilution factors to obtain the actual 
reading for each sample. 
Animals
Rats: All procedures with animals were per-
formed in accordance with the Association for 
Research in Vision and Ophthalmology (ARVO) 
statement for use of animals in ophthalmic and 
vision research and were approved by the insti-
tutional animal care and use committee of the 
College of Pharmacy, King Saud University. 
Adult male Sprague Dawley rats of 8-9 weeks 
of age (200-220 g) were overnight fasted and 
streptozotocin (STZ) 55 mg/kg in 10 mM sodi-
um citrate buffer, pH 4.5; (Sigma, St. Louis, MO) 
was injected intraperitoneally. Equal volumes 
of citrate buffer were injected in age-matched 
control rats. Rats were considered diabetic if 
their blood glucose was greater than 250 mg/
dl. 
Glycyrrhizin (GA) treatment
Diabetic rats were divided into 2 groups: the 
rats in group I received normal drinking water 
without any supplementation, and group II 
received drinking water supplemented with 
glycyrrhizic acid (150 mg/kg/day, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) immediate-
ly after establishment of diabetes. After 4 
weeks of diabetes, the rats were euthanized by 
an overdose of chloral hydrate, the eyes were 
removed, and the retinas were isolated and fro-
zen immediately in liquid nitrogen and stored at 
-80°C until analysis. 
Intravitreal injection of HMGB1
Sprague Dawley rats (220-250 g) were kept 
under deep anesthesia, and a sterilized solu-
tion of recombinant HMGB1 (5 ng/5 μl; R&D 
Systems, Minneapolis, MN) was injected into 
the vitreous of the right eye as previously 
described [32]. For the control, the left eye 
received 5 μl of sterile phosphate buffer saline 
(PBS). Each group consisted of 7-10 rats. The 
animals were sacrificed 4 days after intravitreal 
administration, and the retinas were carefully 
dissected, snap frozen in liquid nitrogen, and 
stored at -80°C until analysis. 
Mice: Wild-type (WT) and MMP-9 knock out 
(MMP-9 KO) mice [41] were backcrossed 13 
times into C57BL6 background, were made dia-
betic by intraperitoneal injection of streptozoto-
cin for five consecutive days. Mice with blood 
glucose above 200 mg/dL, 3 days after the last 
injection of streptozotocin were considered as 
diabetic. Age-matched normal WT mice served 
as controls. Mice were sacrificed by pentobarbi-
tal overdose and the retinas were removed 
from eye, snap frozen in liquid nitrogen, and 
stored at -80°C for RNA isolation. All experi-
ments were performed in accordance to the 
Association of Research in Vision and Oph- 
thalmology (ARVO) and King Saud University’s 
Animal Care and Use Committee Guidelines on 
handling and treatment of animals for basic sci-
entific research.
Cell culture 
HRMEC were purchased from Cell Systems 
Corporation (Kirkland, WA) and maintained in 
complete serum free media (Cat. No. SF-4Z0-
500, Cell System Corporation) supplemented 
with Rocket Fuel (Cat No. SF-4ZO-500, Cell 
System Corporation), Culture Boost (Cat. No. 
4CB-500, Cell System Corporation) and antibi-
otics (Cat. No. 4ZO-643, Cell System 
Corporation) at 37°C in a humidified atmo-
sphere with 5% CO2. We used HRMEC cells up 
to passage 8 for all the experiments. When 
HRMEC cells became ~80% confluent, cells 
were starved in medium without growth factors 
(Rocket Fuel and Culture Boost) overnight to 
eliminate any residual effects of growth fac-
tors. Following starvation, HRMEC were either 
left untreated or treated with 10 μg/ml of cyto-
kine-HMGB 1, lipopolysaccharide free (Cat. No. 
REHM120, IBL International Corp, Toronto, ON) 
or HMGB1 plus 50 ng/ml of MMP-9 inhibitor I 
(CAS 1177749-58-4; Cat. No. sc-311437, 
Santa Cruz Biotechnology, Inc). This dose of 
cytokine-HMGB 1 was based on our previous 
studies [23]. Cells were harvested after 24 
hour in western lysis buffer (30 mM Tris-HCL; 
pH 7.5, 5 mM EDTA, 1% Triton X-100, 250 mM 
sucrose, 1 mM Sodium vanadate and protease 
inhibitor cocktail) for Western blot analysis. 
Real time reverse transcription polymerase 
chain reaction (RT-PCR)
Total RNA was extracted from retina using TRI 
reagent (Ambion, TX), according to the manu-
facturer’s protocol. cDNA were synthesized 
from 1 µg RNA, using an high capacity cDNA 
reverse transcription kit (Applied Biosystem, 
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CA) following manufacturer’s instruction. Real 
time RT-PCR was performed using a SYBR 
green PCR master mix. The PCR primers for rat 
were: MMP-9 forward 5’-CCACCGAGCTATCC- 
ACTCAT-3’ reverse 5’-GTCCGGTTTCAGCATGTT- 
TT-3’; TIMP1 Forward 5’-CTGGCATCCTCTTG- 
TTGCT-3’ and reverse 5’-CACAGCCAGCACTAT- 
AGGTCTTT-3’ and primers for mice were: 
MMP-9 forward 5’-GCAACGGAGACGGCAAAC 
C-3’ and reverse 5’-GACGAAGGGGAAGACGCA-3’; 
β-actin forward 5’-CCTCTATGCCAACACAGT G- 
C-3’ reverse 5’-CATCGTACTCCTGCTTGCTG-3’. 
The standard PCR conditions included 2 min at 
50°C and 10 min at 95°C followed by 40 cycles 
of extension at 95°C for 15 seconds and one 
min at 60°C. Threshold lines were automati-
cally adjusted to intersect amplification lines in 
the linear portion of the amplification curves 
and cycle to threshold (Ct) values were record-
ed automatically. Data were normalized with 
β-actin-mRNA levels (housekeeping gene) and 
the fold change in gene expression relative to 
normal was calculated using the ddCt method.
Western blot analysis
Retinas and cell lysates were homogenized in a 
Western Blot lysis buffer. The lysate was centri-
fuged at 14,000 ×g for 15 min at 4°C and the 
supernatants was collected and equal amounts 
of protein (50 µg) were subjected to SDS-PAGE 
and transferred to nitrocellulose membranes. 
till 80-90% confluence. Quiescence was in- 
duced by incubating the cells in minimal media 
overnight. Scratches were made with a sterile 
pipette tip and then cells were rinsed with PBS. 
Cells were either left untreated or treated either 
with HMGB1 (10 µg/ml) or HMGB1 plus MMP-9 
inhibitor I (50 ng/ml each) for 18 hrs at 37°C in 
a CO2 incubator. Cell migration was monitored 
by visual examination using an inverted micro-
scope (Olympus 1 X 81). Analysis of migration 
was done using Image J software.
 Statistical analysis
The results are presented as mean ± s.d. and 
analyzed statistically using the nonparametric 
Kruskal-Wallis test, followed by the Mann-
Whitney test for multiple group comparisons. 
Pearson correlation coefficients were comput-
ed to investigate correlation between variables. 
A p-value less than 0.05 indicated statistical 
significance. SPSS version 12.0 was used for 
the statistical analyses.
Results
Levels of HMGB1 and MMP-9 in vitreous 
samples
HMGB1 was detected in all vitreous samples 
from patients with PDR (n = 25) and nondiabet-
ic control patients (n = 17). The mean level of 
Figure 1. Correlations. Significant positive correlation between vitreous fluid 
levels of high-mobility group box-1 protein (HMGB1) and levels of MMP-9 in 
vitreous samples from 25 patients with proliferative diabetic retinopathy and 
17 nondiabetic control patients.
Immunodetection was per-
formed using antibodies 
against MMP-9 (1:500; R 
and D systems,) and HMGB-
1 (Abcam, UK). Membranes 
were stripped and reprobed 
with β-actin to evaluate the 
lane-loading control. Bands 
were visualized with the 
use of high-performance 
chemiluminescence mach- 
ine (G: Box Chemi-XX8 fr- 
om Syngene, Synoptic Ltd. 
Cambridge, UK), and the 
intensities were quantified 
by using GeneTools soft-
ware (Syngene by Synoptic 
Ltd.).
In vitro migration assay 
HRMEC were plated at 
1×105 cells/well on 6-well 
culture plates and allowed 
to grow as described above 
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HMGB1 in vitreous samples from PDR patients 
(4436.76 ± 2144.7 pg/mL) was significantly 
higher than the mean level in nondiabetic con-
trol patients (1990.99 ± 363.7 ng/ml) (P < 
0.0001; Mann-Whitney test).
The levels of MMP-9 were measured in 21 vitre-
ous samples from patients with PDR and in 17 
vitreous samples from nondiabetic patients. 
The mean level of MMP-9 in vitreous samples 
from PDR patients (2312.14 ± 1955.7 pg/ml) 
was significantly higher than the mean level in 
nondiabetic control patients (720.29 ± 582 
pg/ml) (P < 0.0001; Mann-Whitney test).
A significant positive correlation was observed 
between vitreous fluid levels of HMGB1 and 
MMP-9 (r = 0.5, P = 0.003) (Figure 1). These 
findings suggested the presence of a mecha-
nistic link between HMGB1 and MMP-9 in the 
pathogenesis of diabetic retinopathy. To vali-
date these clinical observations, we used in 
vitro and in vivo model experiments.
Effect of HMGB1 on MMP-9 expressions in 
HRMEC
To validate the significant positive correlation 
between the vitreous fluid levels of HMGB1 and 
MMP-9, we performed induction experiments 
on HRMEC with HMGB1. Stimulation of HRMEC 
with HMGB1 significantly increased MMP-9 
expression by 42% as compared to untreated 
cells. Co-treatment of HMGB1 and MMP-9 
inhibitor I attenuated significantly HMGB1-
induced upregulation of MMP-9 expression 
(Figure 2A).
Figure 2. Effect of MMP-9 inhibitor on HMGB1-induced MMP-9 expressions and migration in HRMEC: A. Protein 
expressions of MMP-9 in cell lysates were determined by Western blotting. β-actin was used as a loading control. 
Control = untreated cells, H = cells treated with HMGB1 and H + MMP-I = cells treated with HMGB1 plus MMP-9 
inhibitor. B. HMGB1-induced migration of the HRMEC was inhibited by the MMP-9 inhibitor. Cells were visualized us-
ing inverted microscope and six independent field images were taken from each treated group for migration analysis 
which was done by using Image J software. One image from each group is illustrated and the bar graphs show the 
analysis of all six images from each group. *The difference between the two means was statistically significant at 
the 5% level. Data are mean ± SD from three different experiments, each is performed in triplicate. *P < 0.05 com-
pared to control and #P < 0.05 compared to diabetic.
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Effect of HMGB1 and MMP-9 inhibitor on HR-
MEC migration
Stimulation of HRMEC with HMGB1 significantly 
enhances the cell migration. Co-treatment of 
HMGB1 and MMP-9 inhibitor I significantly 
inhibited the migration induced by HMGB1 in 
HRMEC suggesting that MMP-9 mediated the 
HMGB1-induced cell migration in HRMEC 
(Figure 2B).
Intravitreal administration of HMGB1 in-
creased MMP-9 and decreased TIMP-1 mRNA 
levels in the retinas
RT-PCR analysis demonstrated significant 
upregulation of MMP-9 and downregulation of 
TIMP-1 levels in the retinas of HMGB-injected 
eyes compared to PBS-injected eyes. HMGB1 
injection resulted in a 1.5-fold increase in 
MMP-9 mRNA levels when compared with the 
values obtained from contralateral eye that 
received PBS alone (Figure 3A). In the same 
HMGB1 injected eyes samples, TIMP-1 retinal 
mRNA level were decreased compared to PBS-
injected eyes (Figure 3B).  
Severity of hyperglycemia in rats
The body weights of the diabetic rats were 
lower and their blood glucose levels were more 
than four-fold higher compared with age-
matched normal control rats (164 ± 25 vs 297 
± 18 g and 449 ± 27 vs 109 ± 12 mg/dl, 
respectively). Treatment of the diabetic rats 
with glycyrrhizin for one month did not change 
these metabolic variables in the diabetic rats 
(173 ± 27 vs 164 ± 25 g and 463 ± 32 vs 449 
± 27 mg/dl, respectively).   
Glycyrrhizin attenuates diabetes-induced up-
regulation of MMP-9 but not downregulation of 
TIMP-1 in the retinas
RT-PCR analysis demonstrated significant up- 
regulation of MMP-9 mRNA and down regula-
Figure 3. Effect of intravitreal administration of MMP-9 and TIMP-1 mRNA levels in retinas: Gene expression of 
MMP-9 (A) and TIMP-1 (B) was quantified by real-time PCR and was adjusted to the mRNA levels of β-actin in each 
sample. Each measurement was made in duplicate or triplicate. PBS = phosphate buffer saline (PBS) injected eye, 
HMGB1 = HMGB1 injected eye. Data are mean ± SD from retina from 6 rats in each group, *P < 0.05 compared to 
PBS injected eye.
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tion of TIMP-1 in diabetic retinas compared to 
nondiabetic retinas. The mRNA levels of MMP-9 
in the retinas of diabetic rats were significantly 
increased by about twofold as compared to 
nondiabetic rats. In the same diabetic retina 
samples, TIMP-1 mRNA level was decreased by 
0.5 fold when compared with the nondiabetic 
retinas (Figure 4A, 4B). The mRNA levels of 
MMP-9 in the glycyrrhizin-fed diabetic rats were 
significantly lower than those in the untreated 
diabetic rats (P = 0.03) (Figure 4A). Interestingly, 
the level of TIMP-1 mRNA in the retinas from 
glycyrrhizin treated diabetic rats did not change 
as compared to the diabetic rats (P = 0.38) but 
were significantly lower than nondiabetic rats 
(P = 0.02) (Figure 4B).
Effect of targeted deletion of the MMP-9 gene 
on the HMGB1 expression
MMP-9 mRNA level in retina of WT diabetic 
mice was about 1.8 fold higher compared with 
the WT nondiabetic mice. As a control, in 
MMP9-KO mice diabetes had no effect on reti-
nal MMP-9 expression (Figure 5A).
There was a significant increase in the protein 
expression of HMGB1 in retina of WT diabetic 
mice compared to WT nondiabetic and the 
expression level of HMGB1 were did not 
changed in MMP9-KO diabetic mice compared 
with WT diabetic mice (Figure 5B).
Discussion
In the present study, we corroborated that 
HMGB1 and MMP-9 were significantly upregu-
lated in the vitreous fluid from patients with 
PDR. Our results are consistent with previous 
reports in different patient cohorts that demon-
strated increased levels of HMGB1 [29, 30] and 
MMP-9 [3, 4] in the vitreous fluid of PDR 
patients. In addition, we showed a significant 
positive correlation between vitreous fluid lev-
els of HMGB1 and the levels of MMP-9. These 
findings suggest the presence of a mechanistic 
link between HMGB1 and MMP-9 in the patho-
genesis of PDR. Similarly, previous reports 
demonstrated that increased HMGB1 expres-
sion is linked to MMP-9 expression and activa-
tion in several diseases. Significant correlation 
was reported between serum levels of HMGB1 
and MMP-9 in patients with diabetes [36]. In 
patients with ischemic stroke, increased plas-
ma levels of HMGB1 and MMP-9 are associat-
Figure 4. Effect of glycyrrhizin on diabetes-induced alteration MMP-9 and TIMP-1 in the retinas: Gene expression 
of MMP-9 (A) and TIMP-1 (B) in the retinas was quantified by RT-PCR using the specific primers given in the materi-
als and methods section and were adjusted to the mRNA level of β-actin in each sample. Each measurement was 
performed at least three times. Results are presented as mean ± SD of 6 rats in diabetes (Diab) and 7 rats each 
in normal and diabetic + Glycyrrhizin (Diab + GA) groups. *P < 0.05 compared to normal, and #P < 0.05 compared 
to diabetes.
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ed with a poor functional outcome and are sig-
nificantly correlated with each other [37]. In 
non-small cell lung cancer specimens, high 
HMGB1 expression was significantly associat-
ed with clinically advanced stages and was cor-
related to the expression of MMP-9 [38]. In a 
mouse model of abdominal aortic aneurysm, 
the expression of HMGB1 was increased, and 
was positively correlated with MMP-9 activity 
[39].
To corroborate the findings at the cellular level, 
stimulation with HMGB1 caused upregulation 
of MMP-9 in HRMEC. In addition, diabetes and 
intravitreal injection of HMGB1 in normal rats 
induced significant upregulation of the mRNA 
levels of MMP-9 and downregulation of the 
mRNA levels of TIMP-1 in the retinas. Consistent 
with our data, increased expression of MMP-9 
and decreased expression of TIMP-1 have been 
reported in the retinas of diabetic rats [42, 43]. 
In vitro studies showed that HMGB1 upregulat-
ed MMP-9 in neuronal and glial cell cultures 
[44], astrocytes [45] and hepatocarcinoma 
cells [46]. In addition, stereotactic injection of 
HMGB1 directly into normal striatum caused a 
significant upregulation of MMP-9 in striatal 
homogenates [44]. 
In previous studies, we demonstrated that dia-
betes and intravitreal administration of HMGB1 
in normal rats induced significant upregulation 
of the expression of HMGB1, RAGE, activated 
ERK1/2 and activated NF-kB in the retinas [29, 
32-34]. In addition, diabetes increased the 
interaction between HMGB1 and RAGE in the 
retina of rats [32, 35]. Furthermore, in our labo-
ratory, we recently demonstrated that exposure 
of HRMEC to HMGB1 and intravitreal adminis-
tration of HMGB1 in normal rats induced signifi-
cant upregulation of reactive oxygen species 
[47]. In the context of PDR, these pathways may 
be especially relevant because NF-kB and 
ERK1/2 signaling pathways [43, 48] and reac-
tive oxygen species [48, 49] play pivotal role in 
the production and release of MMP-9. We also 
Figure 5. Effect of MMP-9 knocked out on retinal expression of MMP-9 and HMGB1. A. The mRNA level of MMP-9 
was quantified in the retinal homogenate by RT-PCR. B. The expression of HMGB1 was quantified by western blot-
ting using specific antibody and was adjusted to the protein levels of β-actin in each sample. Each measurement 
was performed at least three times. Results are expressed as mean ± s.d. of at least 6 mice in each group. *P < 
0.05 compared with WT nondiabetic mice and #P < 0.05 compared to WT diabetic mouse. WT and WT-D = wild-type 
nondiabetic and diabetic, respectively, and KO-D = MMP-9 knockout diabetic mice.
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demonstrated that HMGB1 induced significant 
upregulation of the angiogenic biomarker vas-
cular endothelial growth factor (VEGF) in 
HRMEC and in the retinas of rats [35]. VEGF 
has been shown to induce MMP-9 expression 
in different cells [9, 50].
Constant glycyrrhizin intake significantly 
reduced diabetes-induced upregulation of 
MMP-9, but did not affect the expression of 
TIMP-1 in the retinas of rats. Glycyrrhizin has 
been shown to bind to, and inhibit mitogenic, 
chemo-attractant and cytokine-like activities of 
HMGB1 [40]. Similarly, previous studies dem-
onstrated that HMGB1 blockade markedly 
reduced MMP-9 expression and activity. 
Treatment with neutralizing anti-HMGB1 mono-
clonal antibody suppressed the expression and 
activity of MMP-9, and ameliorated brain infarc-
tion induced by middle cerebral artery occlu-
sion in rats [51], and suppressed aneurysm 
formation in a mouse model of abdominal aor-
tic aneurysm [39]. Treatment with HMGB1 
small interfering RNA reduced MMP-9 expres-
sion and cellular metastatic ability in gastric 
cancer cells [52] and in non-small cell lung can-
cer cells [38]. Blockade of HMGB1-RAGE axis 
by ethyl pyruvate decreased the expression of 
MMP-9 and inhibited gall bladder cancer cell 
proliferation and invasion [53]. In addition, 
knockdown of RAGE in cancer cells diminished 
HMGB1-induced increased production of 
MMP-9 suggesting that RAGE is required for 
HMGB1 promotion of tumor invasion by 
increased production of active MMP-9 [44].
The results of the present study also show that 
deletion of the MMP-9 gene in MMP-9 gene 
knockout mice did not inhibit diabetes-induced 
HMGB1 upregulation in the retina. In addition, 
our in vitro studies showed that exposure of 
HRMEC to HMGB1 induced MMP-9 expression 
and stimulated HRMEC migration, a key early 
step in angiogenesis. A MMP-9 inhibitor decr- 
eased MMP-9 expression and inhibited HRMEC 
migration induced by HMGB1. Our results indi-
cate that MMP-9 acts downstream of HMGB1 
and that MMP-9 plays a significant role in medi-
ating HMGB1-induced angiogenesis in PDR.
In conclusion, on the basis of our clinical and in 
vitro and in vivo studies, we hypothesize that 
MMP-9 is a downstream effector that plays a 
critical role in HMGB1-dependent angiogenic 
activity in PDR. The ability of HMGB1 to upregu-
late MMP-9 provides a novel mechanism by 
which retinal injury is amplified in patients with 
PDR. Targeting the HMGB1-MMP-9 pathway 
may be a novel therapeutic approach for PDR.  
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